Pseudolaric Acid A: A Promising Antifungal Agent Against Prevalent Non-albicans Candida Species

References

• Bilal H, Shafiq M, Hou B, et al. Distribution and antifungal susceptibility pattern of Candida species from mainland China: a systematic analysis. Virulence. 2022;13(1):1573–1589. doi:10.1080/21505594.2022.2123325
   PubMed Web of Science ®Google Scholar
• Kotey FA-O, Dayie NT, Tetteh-Uarcoo PB, Donkor EA-O. Candida bloodstream infections: changes in epidemiology and increase in drug resistance. Infect Dis. 2021;14:1–5. doi:10.1177/11786337211026927.
   Google Scholar
• Zhang W, Song X, Wu H, and Zheng R. Epidemiology, risk factors and outcomes of Candida albicans vs non- albicans candidaemia in adult patients in Northeast China. Epidemiol Infect. 2019;147:e277. doi:10.1017/S0950268819001638
   PubMed Web of Science ®Google Scholar
• Gómez-Gaviria M, Ramírez-Sotelo U, Mora-Montes HA-O. Non-albicans Candida species: immune response, evasion mechanisms, and new plant-derived alternative therapies. J Fungi. 2023;9(1):11. doi:10.3390/jof9010011
   Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes CG, DeVries S, Huband MD, Castanheira M. Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017–2019. Diagn Microbiol Infect Dis. 2022;102(4):115627. doi:10.1016/j.diagmicrobio.2021.115627
   PubMed Web of Science ®Google Scholar
• Xiao M, Chen SC, Kong F, et al. Distribution and antifungal susceptibility of Candida species causing candidemia in China: an update from the CHIF-NET study. J Infect Dis. 2020;221(Suppl 2):S139–S147. doi:10.1093/infdis/jiz573
   PubMedGoogle Scholar
• Tsay SV, Mu Y, Williams S, et al. Burden of candidemia in the United States, 2017. Clin Infect Dis. 2020;71(9):e449–e453. doi:10.1093/cid/ciaa193
   PubMed Web of Science ®Google Scholar
• Aldejohann AM, Herz M, Martin R, Walther G, Kurzai O. Emergence of resistant Candida glabrata in Germany. JAC Antimicrob Resist. 2021;3(3):dlab122. doi:10.1093/jacamr/dlab122
   PubMedGoogle Scholar
• Al-Musawi TS, Alkhalifa WA, Alasaker NA, Rahman JU, Alnimr AM. A seven-year surveillance of Candida bloodstream infection at a university hospital in KSA. J Taibah Univ Med Sci. 2021;16(2):184–190. doi:10.1016/j.jtumed.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Chapman B, Slavin M, Marriott D, et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72(4):1103–1108. doi:10.1093/jac/dkx047
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan X, Wang H, et al. Continual decline in azole susceptibility rates in Candida tropicalis over a 9-year period in China. Front Microbiol. 2021;12:702839. doi:10.3389/fmicb.2021.702839
   PubMed Web of Science ®Google Scholar
• Khalifa HO, Watanabe A, Kamei K. Azole and echinocandin resistance mechanisms and genotyping of Candida tropicalis in Japan: cross-boundary dissemination and animal-human transmission of C. tropicalis infection. Clin Microbiol Infect. 2022;28(2):302 e305–302 e308. doi:10.1016/j.cmi.2021.10.004
   Web of Science ®Google Scholar
• Canturk Z. Evaluation of synergistic anticandidal and apoptotic effects of ferulic acid and caspofungin against Candida albicans. J Food Drug Anal. 2018;26(1):439–443. doi:10.1016/j.jfda.2016.12.014
   PubMed Web of Science ®Google Scholar
• Behbehani JM, Irshad M, Shreaz S, Karched M. Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral Candida isolates. J Mycol Med. 2019;29(2):158–167. doi:10.1016/j.mycmed.2019.01.011
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren H, Wang D, Zhang M, Sun S, and Zhao Y. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation. Biomed Pharmacother. 2020;130:110580. doi:10.1016/j.biopha.2020.110580
   PubMed Web of Science ®Google Scholar
• Pan M, Wang Q, Cheng T, et al. Paeonol assists fluconazole and amphotericin B to inhibit virulence factors and pathogenicity of Candida albicans. Biofouling. 2021;37(8):922–937. doi:10.1080/08927014.2021.1985473
   PubMed Web of Science ®Google Scholar
• Xu Y, Quan H, Wang Y, et al. Requirement for ergosterol in berberine tolerance underlies synergism of fluconazole and berberine against fluconazole-resistant Candida albicans isolates. Front Cell Infect Microbiol. 2017;7:491. doi:10.3389/fcimb.2017.00491
   PubMed Web of Science ®Google Scholar
• Chiu P, Leung LT, Ko BC. Pseudolaric acids: isolation, bioactivity and synthetic studies. Nat Prod Rep. 2010;27(7):1066–1083. doi:10.1039/b906520m
   PubMed Web of Science ®Google Scholar
• Zhu B, Li Z, Yin H, et al. Synergistic antibiofilm effects of pseudolaric acid A combined with fluconazole against Candida albicans via inhibition of adhesion and Yeast-To-Hypha transition. Microbiol Spectr. 2022;10(2):e0147821. doi:10.1128/spectrum.01478-21
   PubMed Web of Science ®Google Scholar
• Guo N, Ling G, Liang X, et al. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans. Mycoses. 2011;54(5):e400–e406. doi:10.1111/j.1439-0507.2010.01935.x
   PubMed Web of Science ®Google Scholar
• Kollu NV, LaJeunesse DR. Cell rupture and morphogenesis control of the dimorphic yeast Candida albicans by nanostructured surfaces. ACS Omega. 2021;6(2):1361–1369. doi:10.1021/acsomega.0c04980
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Banu H, Gupta MK. Epidemiology and antifungal susceptibility of Candida Species causing blood stream infections: an Eastern India perspective. J Assoc Physicians India. 2021;69(8):11–12.
   PubMedGoogle Scholar
• Reda NM, Hassan RM, Salem ST, Yousef RHA. Prevalence and species distribution of Candida bloodstream infection in children and adults in two teaching university hospitals in Egypt: first report of Candida kefyr. Infection. 2022;51(2):389–395. doi:10.1007/s15010-022-01888-7
   PubMed Web of Science ®Google Scholar
• Dogan O, Yesilkaya A, Menekse S, et al. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: a multicentre observational study by the Turkish Fungal Infections Study Group. Int J Antimicrob Agents. 2020;56(1):105992. doi:10.1016/j.ijantimicag.2020.105992
   PubMed Web of Science ®Google Scholar
• Li W, He P, Huang Y, et al. Selective autophagy of intracellular organelles: recent research advances. Theranostics. 2021;11(1):222–256. doi:10.7150/thno.49860
   PubMed Web of Science ®Google Scholar
• Xu DD, Du LL. Fission yeast autophagy machinery. Cells. 2022;11(7):1086. doi:10.3390/cells11071086
   PubMed Web of Science ®Google Scholar
• Shimamura S, Miyazaki T, Tashiro M, et al. Autophagy-Inducing Factor Atg1 Is Required for Virulence in the Pathogenic Fungus Candida glabrata. Front Microbiol. 2019;10:27. doi:10.3389/fmicb.2019.00027
   PubMed Web of Science ®Google Scholar
• Hu Y, Reggiori F. Molecular regulation of autophagosome formation. Biochem Soc Trans. 2022;50(1):55–69. doi:10.1042/BST20210819
   PubMed Web of Science ®Google Scholar
• Liu J, Wu XD, Li W, Yuan Z, Yang K, Zhao QS. Discovery of pseudolaric acid A as a new Hsp90 inhibitor uncovers its potential anticancer mechanism. Bioorg Chem. 2021;112:104963. doi:10.1016/j.bioorg.2021.104963
   PubMed Web of Science ®Google Scholar
• Wang B, Chen Z, Yu F, et al. Hsp90 regulates autophagy and plays a role in cancer therapy. Tumour Biol. 2016;37(1):1–6. doi:10.1007/s13277-015-4142-3
   PubMedGoogle Scholar
• Pais P, Califórnia R, Galocha M, et al. Candida glabrata transcription factor Rpn4 mediates fluconazole resistance through regulation of ergosterol biosynthesis and plasma membrane permeability. Antimicrob Agents Chemother. 2020;64(9):e00554. doi:10.1128/AAC.00554-20
   PubMed Web of Science ®Google Scholar